Verve Therapeutics Inc [NASDAQ: VERV] jumped around 0.86 points on Monday, while shares priced at $4.12 at the close of the session, up 26.38%.
Compared to the average trading volume of 1.62M shares, VERV reached a trading volume of 31831231 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Verve Therapeutics Inc [VERV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VERV shares is $25.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VERV stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Verve Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 08, 2024. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on April 13, 2023, representing the official price target for Verve Therapeutics Inc stock. Previously, the target price had yet another raise to $21, while Cantor Fitzgerald analysts kept a Neutral rating on VERV stock.
The Average True Range (ATR) for Verve Therapeutics Inc is set at 0.54, with the Price to Sales ratio for VERV stock in the period of the last 12 months amounting to 11.32. The Price to Book ratio for the last quarter was 0.74, with the Price to Cash per share for the same quarter was set at 5.90.
How has VERV stock performed recently?
Verve Therapeutics Inc [VERV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 23.35. With this latest performance, VERV shares dropped by -30.99% in over the last four-week period, additionally sinking by -10.43% over the last 6 months – not to mention a drop of -48.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VERV stock in for the last two-week period is set at 42.88, with the RSI for the last a single of trading hit 48.51, and the three-weeks RSI is set at 41.40 for Verve Therapeutics Inc [VERV]. The present Moving Average for the last 50 days of trading for this stock 6.09, while it was recorded at 3.36 for the last single week of trading, and 5.90 for the last 200 days.
Verve Therapeutics Inc [VERV]: Deeper insight into the fundamentals
Verve Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.65 and a Current Ratio set at 12.65.
Earnings analysis for Verve Therapeutics Inc [VERV]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VERV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Verve Therapeutics Inc go to 6.58%.
Insider trade positions for Verve Therapeutics Inc [VERV]
There are presently around $90.24%, or 95.03%% of VERV stock, in the hands of institutional investors. The top three institutional holders of VERV stocks are: ALPHABET INC. with ownership of 12.35 million shares, which is approximately 14.6618%. BLACKROCK INC., holding 6.62 million shares of the stock with an approximate value of $$32.31 million in VERV stocks shares; and BLACKROCK INC., currently with $$25.69 million in VERV stock with ownership which is approximately 6.3314%.
